Author:
Perry Caroline M.,Plosker Greg L.
Publisher
Springer Science and Business Media LLC
Reference129 articles.
1. National Institute for Clinical Excellence. CG157 Hyperphosphataemia in chronic kidney disease: NICE guideline. 2013. http://guidance.nice.org.uk/CG157/NICEGuidance/pdf/English . Accessed 30 Nov 2013.
2. Kidney Disease Improving Global Outcomes (KDIGO). KDIGO Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Inter. 2009;76(Suppl 113):S1–S130.
3. Sprague SM. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate. Curr Med Res Opin. 2007;23(12):3167–75.
4. Martin P, Wang P, Robinson A, et al. Comparison of dietary phosphate absorption after single doses of lanthanum carbonate and sevelamer carbonate in healthy volunteers: a balance study. Am J Kidney Dis. 2011;57(5):700–6.
5. Di Iorio B, Bellasi A, Russo D. Mortality in kidney disease patients treated with phosphate binders: a randomized study [Erratum appears in Clin J Am Soc Nephrol. 2012 Aug, 7(8), pp. 1370–1]. Clin J Am Soc Nephrol. 2012;7(3):487–93.
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献